A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC

NCT05236608 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Non Small Cell Lung Cancer

Interventions

DRUG: Nivolumab
DRUG: ADG106

Sponsor

National University Hospital, Singapore

Collaborators

[object Object]
[object Object]
[object Object]